May 08, 2026

Phase 3 Win for TED Therapy

Amgen’s subcutaneous TEPEZZA meets phase 3 endpoints in thyroid eye disease

The Ophthalmologist

May 06, 2026

HHS Office for Civil Rights extends compliance deadline for digital accessibility final rule to May 2027

The regulation applies to dental practices that receive federal financial assistance.

ADA News

May 06, 2026

Mass Spec Roundup: Protein Stress, Cannabis Chemistry and Sharks… 

From T cell dysfunction to shark vertebrae, mass spectrometry traces hidden chemistry across cells, crops, foods, and river systems 

The Analytical Scientist

May 05, 2026

AI Boosts Diabetic Eye Care Access

Recent study highlights how integrated AI-assisted DR screening in primary care clinics can improve access and decrease disparity

The Ophthalmologist

May 05, 2026

Weight-loss Drug Response Varies, But Why?

Study links DNA variants to weight loss and side effects

The Pathologist

May 04, 2026

Education Department finalizes student loan rule implementing 2025 law

The U.S. Department of Education released a final rule updating federal student loan regulations under Title IV of the Higher Education Act.

ADA News

May 04, 2026

This Week’s CGT News: CRISPR Hits Phase 3 Milestone

Intellia’s one-time HAE therapy delivers strong results as Cabaletta strikes CAR-T manufacturing deal

The Medicine Maker

May 04, 2026

Next-generation Graft Health Monitoring

Donor-derived cell-free DNA represents a new approach to an old problem in heart transplantation

The Pathologist

May 01, 2026

IL-6 Inhibitor Vamikibart Shows Efficacy Signals in DME Trial

At ARVO 2026, Arshad M. Khanani, MD, MA, FASRS, presented phase 2 data on vamikibart, an IL-6 inhibitor, in diabetic macular edema.

Retinal Physician

May 01, 2026

GA Gene Therapy Interest Increases

Phase I trial results of PulseSight Therapeutics’ PST-611 to be presented at ARVO 2026

The Ophthalmologist